# A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

> **NCT03670810** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1633 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Lasmiditan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03670810
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-24
- **Primary completion:** 2020-06-12
- **Final completion:** 2021-07-08
- **Target enrollment:** 1633 (ACTUAL)
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03670810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03670810, "A Study of Lasmiditan (LY573144) Over Four Migraine Attacks". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03670810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*